ADC Therapeutics shares surge 15.22% premarket on positive LOTIS-7 trial data showing 89.8% ORR and 77.6% CR rates in DLBCL patients.

ADC Therapeutics surged 15.22% in premarket trading following the announcement of updated data from the LOTIS-7 Phase 1b trial of ZYNLONTA® in combination with glofitamab. The trial demonstrated an 89.8% overall response rate (ORR) and 77.6% complete response (CR) rate in 49 evaluable patients with relapsed or refractory diffuse large B-cell lymphoma, with a manageable safety profile. The data, presented ahead of a scheduled conference call, highlighted the therapy’s potential as a best-in-class combination for second-line and beyond DLBCL treatment. The company also outlined plans to share full results at a medical congress by year-end and submit for regulatory review, reinforcing confidence in ZYNLONTA’s pipeline progress. The strong efficacy metrics and positive safety profile directly drove the sharp premarket rally.